Menu
Search
|

Menu

Close
X

Celsion Corp CLSN.OQ (NASDAQ Stock Exchange Capital Market)

2.06 USD
-- (--)
As of Nov 14
chart
Previous Close 2.06
Open --
Volume --
3m Avg Volume 23,036
Today’s High --
Today’s Low --
52 Week High 3.95
52 Week Low 1.81
Shares Outstanding (mil) 17.91
Market Capitalization (mil) 38.51
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.717
FY17
-3.509
FY16
-11.928
FY15
-14.610
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
77.02
22.95
Price to Book (MRQ)
vs sector
1.99
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
48.16
15.47
LT Debt to Equity (MRQ)
vs sector
48.16
11.13
Return on Investment (TTM)
vs sector
-69.91
13.00
Return on Equity (TTM)
vs sector
-178.78
14.69

EXECUTIVE LEADERSHIP

Jeffrey Church
Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer, Since 2014
Salary: $293,485.00
Bonus: $71,352.00
Khursheed Anwer
Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy, Since 2014
Salary: $154,731.00
Bonus: $55,964.00
Nicholas Borys
Senior Vice President and Chief Medical Officer, Since 2014
Salary: $346,876.00
Bonus: $90,590.00
Michael Tardugno
Executive Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $462,422.00
Bonus: $298,803.00
Donald Braun
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP   NJ   08648-2317

Phone: +1609.8969100
Site: celsion.com/

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

SPONSORED STORIES